The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

In this video, Suneel Kamath, MD, discussed the approval of encorafenib (Braftovi, Array BioPharma) in combination with cetuximab (Erbitux, ImClone) and fluorouracil-based chemotherapy in metastatic ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...

Metastatic colorectal cancer (mCRC) harbouring BRAF mutations, most frequently the V600E variant, accounts for approximately 8–12% of cases and is associated with aggressive clinical behaviour and ...

The study, "BRAF oncogenic mutants evade autoinhibition through a common mechanism," published in Science, was conducted by co-first authors Hugo Lavoie, Ting Jin and Driss Lajoie, all of IRIC, in ...

The BRAF V600E mutation, characterised by a substitution of valine to glutamic acid at codon 600, is present in approximately 10–15 % of colorectal cancers and defines a clinically and biologically ...

The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...